

Clinical Correlates of Patients With Rapid-Cycling Bipolar Disorder and a Recent History of Substance Use Disorder: A Subtype Comparison From Baseline Data of 2 Randomized, Placebo-Controlled Trials

Keming Gao, M.D., Ph.D.; Marcia L. Verduin, M.D.;
David E. Kemp, M.D.; Bryan K. Tolliver, M.D., Ph.D.; Stephen J. Ganocy, Ph.D.;
Omar Elhaj, M.D.; Sarah Bilali, M.S.; Kathleen T. Brady, M.D., Ph.D.;
Robert L. Findling, M.D.; and Joseph R. Calabrese, M.D.

Objective: To compare clinical variables in patients with rapid-cycling bipolar I or II disorder and a recent history of substance use disorder (SUD).

Method: Cross-sectional data from 2 studies of patients with rapid-cycling bipolar I disorder or rapid-cycling bipolar II disorder and a recent history of SUD were used to retrospectively assess the differences in clinical variables between the subtypes. The studies were conducted from November 1997 to February 2007 at University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio. Extensive clinical interview and the Mini-International Neuropsychiatric Interview were used to ascertain DSM-IV diagnoses of rapid-cycling bipolar disorder, SUDs, and other Axis I disorders and to collect clinical variables. The Addiction Severity Index (ASI), Global Assessment Scale (GAS), and the Medical Outcomes Study 36-Item Short-Form Health Survey were used to measure the severity of impairment at the initial assessment. One-way analysis of variance or χ^2 was used for significance tests. A Bonferroni adjustment was applied for multiple comparisons.

Results: Of 245 patients with rapid-cycling bipolar disorder (rapid-cycling bipolar I disorder, N = 191; rapid-cycling bipolar II disorder, N = 54) and a recent history of SUD, the demographics were similar. A significantly higher rate of panic disorder was observed in patients with rapid-cycling bipolar I disorder than in those with rapid-cycling bipolar II disorder (odds ratio = 3.72, 95% CI = 1.66 to 8.32, $p = .008$). A significantly higher psychiatric composite score on the ASI was also found in patients with rapid-cycling bipolar I disorder than in those with rapid-cycling bipolar II disorder even after Bonferroni adjustment ($p = .0007$). There were no significant differences between the subtypes in the rates of previous hospitalization or suicide attempt, early childhood verbal, physical, or sexual abuse, lifetime substance abuse or dependence, the number of SUDs or mood episodes in the last 12 months, and total or other subscale scores on ASI and GAS.

Conclusion: Except for the significantly higher rate of comorbid panic disorder and higher psychiatric composite scores on the ASI in patients with rapid-cycling bipolar I disorder than in those with rapid-cycling bipolar II disorder, the other clinical variables were similar between the 2 groups.

Trial Registration: clinicaltrials.gov Identifiers NCT00194129 and NCT00221975

(*J Clin Psychiatry* 2008;69:1057–1063)

Received Aug. 9, 2006; accepted Nov. 11, 2007. From the Department of Psychiatry, Bipolar Disorder Research Center at the Mood Disorders Program, Case Western Reserve University School of Medicine, University Hospitals Case Medical Center, Cleveland, Ohio (Drs. Gao, Kemp, Ganocy, Elhaj, Findling, and Calabrese and Ms. Bilali); and the Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston (Drs. Verduin, Tolliver, and Brady).

Supported by the Stanley Medical Research Institute, P20 MH-66054 (J.R.C. and R.L.F.), HRSA 1 C76HF00502-01 (J.R.C.), R21 MH-62650 (J.R.C.), R01 MH-50165 (J.R.C.), and Supplement to R01 MH-50165 (J.R.C.).

The authors thank Mark Woyshtville, M.D., Melvin D. Shelton, M.D., Ph.D., and Daniel J. Rapport, M.D., for their clinical work and Carla Conroy for her statistical assistance. Drs. Woyshtville, Shelton, and Rapport were and Ms. Conroy is affiliated with the Mood Disorders Program, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, and their participation was funded by the grants from the Stanley Medical Research Institute and the National Institute of Mental Health mentioned above.

Financial disclosure appears at the end of the article.

Corresponding author and reprints: Keming Gao, M.D., Ph.D., 11400 Euclid Ave., Suite #200, Cleveland, OH 44106 (e-mail: keming.gao@uhhospitals.org).

The differences between bipolar disorder types I and II were defined by the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition (DSM-IV),¹ based mainly on the severity of symptoms, functional impairments, and duration of manic/hypomanic episodes. However, other differences between the 2 types have also begun to emerge. In prospective longitudinal studies, patients with bipolar II disorder experience 39 times more follow-up weeks with depressive symptoms than with

Table 1. Studies of Patients With Rapid-Cycling Bipolar Disorder and Recent Substance Use Disorder

Study Information	Study 1 (N = 149) ^a	Study 2 (N = 96) ^b
Study design	Open-label stabilization with lithium + divalproex for up to 24 wk; protocol-defined responders receiving lithium + divalproex or lithium + placebo for 24 wk; a placebo-controlled discontinuation maintenance study	Open-label treatment with lithium + divalproex for up to 24 wk; protocol-defined nonresponders receiving lithium + divalproex + placebo or lithium + divalproex + lamotrigine for 6 wk; a placebo-controlled acute depression efficacy study
Mood state	Manic/hypomanic/mixed within 3 mo; any mood at screening/baseline	Major depressive episode at screening/baseline
Inclusion criteria	Bipolar I or II disorder, rapid cycling within last 12 mo, ≥ 16 y old; no contraindication to lithium or divalproex; substance abuse/dependence within last 6 mo	Bipolar I or II disorder, rapid cycling within last 12 mo, ≥ 16 y old; no contraindication to lithium, divalproex, or lamotrigine; substance abuse within 3 mo, dependence within 6 mo
Exclusion criteria	Contraindications to lithium levels of 0.8 mEq/L or divalproex levels of 50 µg/mL	Contraindications to lithium, divalproex, or lamotrigine
Data collection	November 1997 to September 2006; study was completed	July 2002 to February 2007; study was ongoing

^aClinicalTrials.gov identifier NCT00194129.^bClinicalTrials.gov identifier NCT00221975.

hypomanic symptoms, whereas bipolar I disorder patients only experience 3 to 4 times more follow-up weeks with depressive symptoms than with manic symptoms.^{2,3} Patients with bipolar I disorder and those with bipolar II disorder also respond to treatments differently. It has been reported that patients with bipolar II disorder are less likely to have antidepressant-induced manic/hypomanic switches than those with bipolar I disorder.^{4,5} On the other hand, patients with bipolar II disorder may benefit more from lithium maintenance treatment than those with bipolar I disorder.⁶

Comorbid substance use disorder (SUD) in bipolar disorders is a rule, not an exception.^{7–10} A higher rate of SUD in patients with bipolar I disorder than in those with bipolar II disorder was observed in the Epidemiologic Catchment Area (ECA) study⁷ and some clinical studies.^{11,12} There are studies comparing the historical correlates and/or comorbidities between the 2 subtypes.^{11,13–20} However, there has never been a study comparing the clinical correlates in patients with bipolar I disorder or bipolar II disorder and a recent history of SUD. Such information is important and can be useful for future research and clinical management in this subgroup of patients with bipolar disorder. Therefore, this study utilized a dataset at initial assessment of patients with rapid-cycling bipolar I or II disorder and a recent history of SUD who participated in 2 similar clinical trials to compare clinical variables according to the subtypes, rapid-cycling bipolar I disorder versus rapid-cycling bipolar II disorder.

METHOD

Patient Population

Cross-sectional data of a cohort of patients with rapid-cycling bipolar disorder who were recruited for 2 randomized, double-blind, placebo-controlled clinical trials were analyzed retrospectively. (The www.clinicaltrials.gov identifiers were NCT00194129 for study 1 and

NCT00221975 for study 2.) The studies were conducted from November 1997 to February 2007 at the Bipolar Disorder Research Center of the Mood Disorders Program at University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio. The studies were conducted to assess the efficacy of different regimens for managing the acute and maintenance treatment of rapid-cycling bipolar disorder accompanied by a “recent” history of SUD. Patients who had a diagnosis of substance dependence and continued to meet abuse or dependence criteria for 1 or more substances in the past 6 months at the initial assessment (study 1 and study 2) or those who had a diagnosis of substance abuse and had continued abusing a substance in the last 3 months (study 1) or 6 months (study 2) were considered to have a recent history of SUD. The patients were referred from specialty clinics, private and public mental health centers, and advertisements. The respective institutional review boards’ approval was obtained, and patients provided written, informed consent for each study. The study designs, study index, inclusion and exclusion criteria, and stages of the 2 studies at the time of this analysis are summarized in Table 1.

Initial Assessments

Diagnoses of rapid-cycling bipolar disorder, anxiety disorders (including generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder), SUDs, and other DSM-IV Axis I disorders were ascertained by extensive clinical interview (ECI) and the Mini-International Neuropsychiatric Interview (MINI)²¹ by research psychiatrists and research assistants. The ECI, which is similar to the Structured Clinical Interview for the DSM-IV, Patient Edition (SCID-P),²² consists of questions and criteria for the diagnosis of DSM-IV Axis I disorders but also contains items to assess mental status, severity of suicidality, demographics, and other variables of interest. The ECI and the MINI combination typically

included a 60- to 90-minute initial interview done by a Master's level research assistant and a 30- to 45-minute second evaluation carried out by a research psychiatrist who confirmed bipolar diagnosis, a recent history of substance use disorder, and other findings from the first visit. A certified research assistant administered the MINI at the third visit to confirm and expand the diagnoses of other Axis I disorders. For the MINI certification, a minimal κ of 0.8 on 10 cases rating against a leading rater who was certified by the Systematic Treatment Enhancement Program for Bipolar Disorder²³ was required. The agreement between the ECI and the MINI diagnosis was over 90%. If any inconsistency occurred with the first and second evaluations during the MINI administration, a psychiatrist would reevaluate the patient. For the diagnosis of substance use disorders, the SCID-P was used instead of the MINI at the third visit.

The severity of SUDs was assessed with the Addiction Severity Index (ASI),²⁴ which is designed to detect and measure the severity of potential treatment problems; the ASI focuses on the past 30 days in 7 areas commonly affected by alcohol and drug dependence, including medical, employment, alcohol, drugs, legal, family/social, and psychiatric problems. Overall function and health conditions were assessed with the Global Assessment Scale (GAS)²⁵ and the Medical Outcomes Study 36-Item Short-Form Health Survey-36 (SF-36).²⁶ The SF-36 is a multi-purpose, short-form health survey with 36 questions that assess functional status (physical functioning, social functioning, role limitations—physical and emotional problems), well-being (mental health, vitality, and pain), and overall evaluation of health (general health perception and health change). Collateral information from the mandatory presence of a patient's significant other(s) was required in all cases during the initial assessment. Patients who met anxiety disorder criteria prior to or at the time of initial assessment were considered to have a lifetime history of anxiety disorder. Patients who met substance abuse or dependence criteria prior to or at the initial assessment were considered to have a lifetime history of SUD.

Procedures

Data from the initial assessment of the 2 studies were merged into one dataset and analyzed based on bipolar subtypes, rapid-cycling bipolar I disorder versus rapid-cycling bipolar II disorder. Historical variables, including health insurance status, comorbid anxiety disorders and SUDs, previous history of hospitalization, suicide attempt, or early childhood abuse, and recent clinical variables, including ASI composite scores, GAS scores, SF-36 physical and mental component scores, and numbers of episodes in the last 12 months, were compared. Any SUD meant the presence of alcohol or drug (legal or illegal) abuse or dependence except for caffeine and nico-

tine. Any anxiety disorder meant the presence of generalized anxiety disorder, panic disorder, and/or obsessive-compulsive disorder.

Statistical Analysis

All analyses were based on the assumption that the data were normally distributed. The hypotheses were that patients with bipolar I disorder would have higher rates or scores of these clinical variables than would those with bipolar II disorder. Analysis of variance was used to analyze the continuous variables and standard deviation was used to reflect the magnitude of variance. For categorical data, χ^2 tests were used for significance testing. Odds ratios were used for risk estimate and are presented with CIs. Given the exploratory nature of the study, statistical significance was set at $\alpha = .05$, 2-tailed, in order to detect potentially clinically meaningful associations. The 95% CI presents with the mean \pm 1.96 SE. Because multiple comparisons occurred, a simple Bonferroni adjustment was applied. Accordingly, the adjusted p value for each comparison equals $.05/45 = 0.0011$.

RESULTS

Demographics and Lifetime Clinical Correlates

As shown in Table 2, at the initial assessment there was no difference in the mean age at study entry, sex, or insurance status between those with rapid-cycling bipolar I disorder and rapid-cycling bipolar II disorder. In terms of the number of lifetime comorbid Axis I disorders, significantly fewer patients with rapid-cycling bipolar I disorder had only 1 comorbid disorder than those with rapid-cycling bipolar II (6.8% vs. 20.4%, $p = .003$) before Bonferroni adjustment. However, patients with rapid-cycling bipolar I had significantly higher rates of any comorbid anxiety disorder (62.3% vs. 38.9%, $p = .0021$), generalized anxiety disorder (52.4% vs. 27.8%, $p = .0013$), and panic disorder (39.3% vs. 14.8%, $p = .0008$) than those with rapid-cycling bipolar II disorder before Bonferroni adjustment. Moreover, only the difference in panic disorder was still significant after adjustment for multiple comparisons. There were no significant differences between bipolar subtypes, in the rates of lifetime history of hospitalization, suicide attempt, or substance use disorders, as a group or individually, in rates of early childhood abuse or the number of lifetime substance use disorders.

Severity Measurements at the Initial Assessment

As shown in Table 3, among the ASI composite scores of the 7 areas, only mean \pm SD psychiatric subscores were significantly different between the 2 subtypes even after the Bonferroni adjustment (0.59 ± 0.14 vs. 0.51 ± 0.15 , $p = .0007$). In terms of the number of mood episodes over the past 12 months, there was no significant differ-

Table 2. Comparisons of Demographics and Historical Correlates Between Patients With RCBPI and RCBPII With a Recent History of Substance Use Disorder

Characteristic	RCBPI (N = 191)		RCBPII (N = 54)		RCBPI vs RCBPII		
	Mean	SD	Mean	SD	OR	Wald 95% CI	p
Age at study entry, y	36	9.9	35.3	10.4671
	N	%	N	%			
Sex							
Male	122	63.9	32	59.3	1.22	0.66 to 2.26	.5354
Female	69	36.1	22	40.7
Health insurance status at baseline							
None	90	47.1	29	53.7	1.08	0.61 to 1.90	.802
Commercial	71	37.4	22	40.7	0.86	0.46 to 1.60	.633
Medicaid/Medicare/Veterans Administration	29	15.3	5	9.3	1.75	0.64 to 4.78	.266
Lifetime comorbid Axis I disorders, no. ^a							
1	13	6.8	11	20.4	0.29	0.12 to 0.68	.003
2	36	18.9	12	22.2	0.81	0.39 to 1.70	.581
3	48	25.3	11	20.4	1.31	0.63 to 2.75	.470
4	40	21.1	7	13.0	1.78	0.75 to 4.23	.189
≥ 5	53	27.9	13	24.1	1.21	0.60 to 2.44	.591
Lifetime comorbid anxiety disorders							
Any	119	62.3	21	38.9	2.60	1.40 to 4.83	.0021
Generalized anxiety disorder	100	52.4	15	27.8	2.86	1.48 to 5.53	.0013
Panic disorder	75	39.3	8	14.8	3.72	1.66 to 8.32	.0008*
Obsessive-compulsive disorder	14	7.3	5	9.3	0.78	0.27 to 2.26	.6397
Lifetime history							
Hospitalization	135	71.4 ^c	35	66.0 ^d	1.31	0.69 to 2.48	.4089
Suicide attempt	90	47.6 ^c	19	35.8 ^d	1.64	0.88 to 3.07	.1191
Early childhood history							
Verbal abuse	90	50.3 ^e	21	45.7 ^g	1.40	0.76 to 2.59	.2833
Physical abuse	70	38.9 ^f	14	30.4 ^g	1.65	0.84 to 3.25	.1427
Sexual abuse	47	26.3 ^e	7	15.6 ^h	2.19	0.93 to 5.18	.0683
Lifetime dependence							
Any	176	92.1	49	90.7	1.20	0.42 to 3.46	.739
Alcohol	131	69.3 ^c	37	69.8 ^d	1.00	0.52 to 1.92	.9924
Marijuana	63	33.7 ⁱ	13	24.5 ^d	1.55	0.78 to 3.10	.2113
Cocaine	74	39.6 ⁱ	16	30.2 ^d	1.50	0.78 to 2.89	.2199
Others ^b	32	16.8	7	13.0	1.35	0.56 to 3.26	.5013
Lifetime abuse							
Any	115	60.2	32	59.3	1.04	0.56 to 1.93	.8998
Alcohol	40	21.2 ^c	12	22.6 ^d	0.93	0.45 to 1.92	.839
Marijuana	55	29.4 ⁱ	21	39.6 ^d	0.64	0.34 to 1.19	.1568
Cocaine	29	15.5 ⁱ	9	17.0 ^d	0.90	0.40 to 2.03	.7903
Others ^b	53	27.7	13	24.1	1.21	0.60 to 2.44	.5909
Lifetime substance use disorders, no.							
1	43	22.6	16	29.6	0.69	0.35 to 1.34	.2801
2	41	21.6	13	24.1	0.86	0.42 to 1.76	.6831
3	60	31.6	9	16.7	2.29	1.05 to 4.99	.0333
≥ 4	46	24.2	16	29.6	0.75	0.39 to 1.48	.4078

^aIncluding anxiety disorders and substance use disorders.^bIncluding stimulants, sedatives, opiates, and hallucinogens.^cPercentage based on N = 189.^dPercentage based on N = 53.^ePercentage based on N = 179.^fPercentage based on N = 180.^gPercentage based on N = 46.^hPercentage based on N = 45.ⁱPercentage based on N = 187.

*Still significant after Bonferroni adjustment (.05/45); the adjusted p value = .0011.

Abbreviations: OR = odds ratio, RCBPI = rapid-cycling bipolar I disorder, RCBPII = rapid-cycling bipolar II disorder.

Symbol: ... = not applicable.

ence between the 2 subtypes in mania/hypomania, depression, or total episodes. Both groups also had a similar GAS score indicative of a moderate impairment in global functioning.

For the SF-36 analysis, there were only 99 patients available (rapid-cycling bipolar I disorder, N = 85, rapid-cycling bipolar II disorder, N = 14). Mean \pm SD physical

component scores were significantly lower in patients with rapid-cycling bipolar I disorder, 56.8 ± 15.2 than those with rapid-cycling bipolar II disorder, 65.4 ± 13.9 (95% CI = -15.0 to -2.1 , $p = .013$). There was no significant difference in the mean \pm SD mental component scores, 36.7 ± 13.6 versus 38.5 ± 17.8 (95% CI = -10.5 to 4.9 , $p = .483$).

Table 3. Comparisons of Clinical Variables at Initial Assessment Between Patients With RCBPI and RCBPII and a Recent History of Substance Use Disorder

Variable	RCBPI (N = 191)		RCBPII (N = 54)		RCBPI vs RCBPII	
	Mean	SD	Mean	SD	Wald 95% CI	p
Addiction Severity Index composite scores						
Medical	0.25	0.32	0.19	0.3	−0.03 to 0.15	.2044
Employment	0.46	0.29	0.41	0.27	−0.03 to 0.13	.2418
Alcohol	0.27	0.24	0.31	0.23	−0.11 to 0.13	.2677
Drug	0.09	0.1	0.09	0.09	−0.03 to 0.03	1.0000
Legal	0.1	0.18	0.12	0.21	−0.08 to 0.04	.5272
Family/social support	0.32	0.25	0.27	0.21	−0.02 to 0.12	.1415
Psychiatric	0.59	0.14	0.51	0.15	0.04 to 0.13	.0007*
Total	0.3	0.1	0.28	0.09	−0.01 to 0.05	.1614
Episodes in past 12 mo, no.						
Mania/hypomania	6.8	4.86	6.35	4.26	−0.88 to 1.78	.5075
Depression	6.91	5.72	6.41	4.27	−0.90 to 1.90	.4855
Total	13.71	10.12	12.76	8.51	−1.74 to 3.64	.4884
Global Assessment Scale scores	51.15	7.46	53.57	7.53	−4.69 to −0.15	.0405

*Still significant after Bonferroni adjustment (.05/45); the adjusted p value = .0011.

Abbreviations: RCBPI = rapid-cycling bipolar I disorder, RCBPII = rapid-cycling bipolar II disorder.

DISCUSSION

In patients with rapid-cycling bipolar disorder and a recent history of SUD, we found that those with rapid-cycling bipolar I disorder and those with rapid-cycling bipolar II disorder had more similarities than differences in terms of lifetime historical correlates, severity of recent SUDs, global functioning, and overall health conditions. However, the rate of comorbid panic disorder and ASI psychiatric composite scores in patients with rapid-cycling bipolar I differed significantly from those with rapid-cycling bipolar II. The ASI psychiatric subscale covers severity of depression and anxiety; trouble understanding, concentrating, or remembering; violent behavior; thoughts of suicide or attempted suicide; experience of psychosis; or psychological or emotional problems in the past 30 days. The difference in SF-36 physical component (physical functioning, role-physical, bodily pain, and general health) scores also suggested that patients with rapid-cycling bipolar I disorder may have a more severe physical problem than those with rapid-cycling bipolar II disorder.

These findings are consistent with previous studies indicating that, while both bipolar subtypes are disabling disorders, and there are similarities between them, important differences do exist between the subtypes.^{13–17} For instance, in a National Institute of Mental Health Collaborative Depression Study, Judd and colleagues¹⁴ found that psychosocial impairment increases significantly with each increment in depressive symptom severity, with equal impairments across bipolar I disorder and bipolar II disorder. The psychosocial impairment also significantly increases with increments in manic symptoms for bipolar I disorder. However, subsyndromal hypomanic symptoms

are not disabling in bipolar II disorder and may even enhance functioning. Similarly, Maina and colleagues¹⁵ reported that euthymic patients with bipolar disorder had lower mean scores on the SF-36 compared to those without a psychiatric disorder, similar to euthymic patients with major depressive disorder. However, in a subgroup analysis, bipolar II disorder was associated with poor health-related quality of life compared to those with bipolar I disorder during the sustained periods of euthymia. On the contrary, the same group of investigators observed that the negative impact of comorbid anxiety disorders on quality of life was restricted to those with bipolar I disorder but not to those with bipolar II disorder, which is consistent with our results.¹⁶

Clearly, the relationship between quality of life and bipolar subtypes warrants further investigation with a larger group of patients.

The similar clinical presentations of patients with rapid-cycling bipolar I disorder and those with rapid-cycling bipolar II disorder in this study should not serve to deemphasize the differences between the subtypes. One such important area is the difference in SUD prevalence. The ECA study data showed that patients with bipolar I disorder had higher rates of SUD than those with bipolar II disorder.⁷ Our previous analysis²⁷ in a larger sample of patients with rapid-cycling bipolar disorder also showed that patients with rapid-cycling bipolar I disorder had significantly higher rates of SUDs than those with rapid-cycling bipolar II disorder. Higher rates of comorbid SUDs in patients with bipolar I disorder (42%–78%) compared to those with bipolar II disorder (17%–48%) has been reported in other studies.^{11,12,28,29}

The finding of similar levels of severity of SUD between these 2 groups of patients has a very important clinical implication. It is well known that the impairment in social, occupational, or other areas of functioning is universal to patients with SUDs. However, the magnitude of impairment often varies dramatically, mainly depending on the class and numbers of substances of abuse/dependence. In a study comparing women with posttraumatic stress disorder and comorbid cocaine or alcohol dependence, it was found that patients with cocaine dependence demonstrated greater social and occupational impairment, more legal problems, and more frequent partner violence compared to those with alcohol dependence.^{30,31} It has also been reported that the severity of SUD intensifies as the number of different substances of abused/dependence increases.^{32,33} Moreover, patients with polysubstance abuse/dependence are at increased risk for

violence and legal complications as well as reduced work productivity.³⁴ The results from this study suggest that patients with bipolar II disorder and a recent history of SUD deserve attention equal to their bipolar I disorder counterparts.

The association between bipolar disorder and panic disorder has been reported by other investigators.^{35–41} Family and genetic studies have shown that bipolar-panic comorbidity is heritable,^{36–38} and comorbid panic disorder increases the risk for rapid mood switching.³⁵ It remains unclear whether this association is subtype specific. A numerical increase in the rate of panic disorder in patients with bipolar I disorder compared to those with bipolar II disorder was observed in some previous studies^{11,20} but not in others.^{19,42} Comorbid panic disorder may pose additional challenges for the treatment of bipolar disorder, as these patients may be less responsive to conventional treatment and require a longer duration to achieve recovery.^{43,44}

These findings must be considered in view of several methodological limitations. First, data obtained in this study were cross-sectional. Second, only the diagnosis of a lifetime anxiety disorder was available for analysis, and not all anxiety disorders were assessed. Third, depending on the recall of history by patients and significant others, the diagnoses and clinical correlates might not be accurate, although the required presence of significant others was intentionally used to minimize such potential inaccuracy. Fourth, our sample only included outpatients with rapid-cycling bipolar disorder and might be less generalizable to other bipolar populations. Despite these limitations, our study has strengths. First, to our knowledge, this is the first report in patients with rapid-cycling bipolar disorder to compare the clinical variables between subtypes. Second, our sample included only patients with a recent history of SUD, which other studies did not study or did not analyze.^{7,11,18}

CONCLUSIONS

Patients with rapid-cycling bipolar I disorder and a recent history of SUD had more similarities to than differences from those with rapid-cycling bipolar II disorder and the same history. Therefore, they should be treated equally and seriously with a systematic multi-disciplined approach. The significantly higher rate of comorbid panic disorder in patients with rapid-cycling bipolar I disorder may add challenges for managing this subgroup of patients.

Drug names: divalproex (Depakote), lamotrigine (Lamictal and others), lithium (Lithobid, Eskalith, and others).

Financial disclosure: Dr. Gao has been a consultant to, received honoraria from, and been a member of the speakers/advisory boards for AstraZeneca and has received grant/research support from Abbott, GlaxoSmithKline, AstraZeneca, and the National Association for Re-

search on Schizophrenia and Depression. Dr. Verduin has received grant/research support from Bristol-Myers Squibb. Dr. Kemp has been a consultant to Bristol-Myers Squibb, Abbott, Wyeth, and Kappa Clinical Partners. Dr. Tolliver has received grant/research support from Forest. Dr. Findling has received research support from, has been a consultant to, and/or has been a member of speakers/advisory boards for Abbott, AstraZeneca, Bristol-Myers Squibb, Cypress Biosciences, Forest, GlaxoSmithKline, Johnson & Johnson, Lilly, Neuropharm, New River, Novartis, Organon, Otsuka, Pfizer, sanofi-aventis, Sepracor, Shire, Solvay, Supernus Pharmaceuticals, and Wyeth. Dr. Calabrese has received grant/research support from the Department of Defense, the National Institute of Mental Health, the Health Resources Services Administration, the Cleveland Foundation, the National Alliance for Research on Schizophrenia and Depression, Repligen, the Stanley Medical Research Institute, Abbott, AstraZeneca, GlaxoSmithKline, Janssen, and Lilly and has been a member of the speakers/advisory boards for Abbott, AstraZeneca, Bristol-Myers Squibb, the France Foundation, GlaxoSmithKline, Janssen, Johnson & Johnson, and Solvay/Wyeth. Drs. Ganocy, Elhaj, and Brady and Ms. Bilali report no financial or other relationship relevant to the subject of this article.

REFERENCES

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. *Arch Gen Psychiatry* 2002;59:530–537
3. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. *Arch Gen Psychiatry* 2003;60:261–269
4. Amsterdam JD, Shults J, Brunswick DJ, et al. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression-low manic switch rate. *Bipolar Disord* 2004;6:75–81
5. Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. *Am J Psychiatry* 2006;163:313–315
6. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium maintenance treatment of depression and mania in bipolar I and II disorders. *Am J Psychiatry* 1998;155:638–645
7. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. *JAMA* 1990;264:2511–2518
8. Kessler RC, Rubinow DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. *Psychol Med* 1997;27:1079–1089
9. Grant BF, Stinson FS, Hasin DS, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and Axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* 2005;66:1205–1215
10. Bauer MS, Altshuler L, Evans DR, et al. Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. *J Affect Disord* 2005;85:301–315
11. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. *Am J Psychiatry* 2001;158:420–426
12. Suppes T, Leverich GS, Keck PE, et al. The Stanley Foundation Bipolar Treatment Outcome Network, 2: demographics and illness characteristics of the first 261 patients. *J Affect Disord* 2001;67:45–59
13. Judd LL, Akiskal HS, Schettler PJ, et al. The comparative clinical phenotype and longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorder? *J Affect Disord* 2003;73:19–32
14. Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders. *Arch Gen Psychiatry* 2005;62:1322–1330
15. Maina G, Albert U, Bellodi L, et al. Health-related quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes. *J Clin Psychiatry* 2007;68:207–212
16. Albert U, Rosso G, Maina G, et al. Impact of anxiety disorder comorbidity on quality of life in euthymic bipolar disorder patients: differences

- between bipolar I and II subtypes. *J Affect Disord* 2008;105:297–303
17. Joffe RT, MacQueen GM, Marriott M, et al. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or II disorders. *Bipolar Disord* 2004;6:62–66
 18. Chengappa KNR, Levine J, Gershon S, et al. Lifetime prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders in a voluntary registry. *Bipolar Disord* 2000;2:191–195
 19. Levander E, Frye MA, McElroy S, et al. Alcoholism and anxiety in bipolar illness: differential lifetime anxiety comorbidity in bipolar I women with and without alcoholism. *J Affect Disord* 2007;101:211–217
 20. Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Am J Psychiatry* 2004;161:2222–2229
 21. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998;59(suppl 20):22–33
 22. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Patient Version. Washington, DC: American Psychiatric Press; 1997
 23. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Biol Psychiatry* 2003;53:1028–1042
 24. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index. *J Nerv Ment Dis* 1980;168:26–33
 25. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. *Arch Gen Psychiatry* 1976;33:766–771
 26. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36), 1: conceptual framework and item selection. *Med Care* 1992;30:473–483
 27. Gao K, Ganocy SJ, Bilali S, et al. Pragmatic considerations in the comorbid presentations of anxiety disorder and substance use disorder in patients with rapid cycling bipolar disorder. In: New Research Program and Abstracts of the 159th Annual Meeting of the American Psychiatric Association; May 20–25, 2006; Toronto, Canada. Abstract NR 51:21
 28. Frye MA, Altshuler LL, McElroy SL, et al. Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. *Am J Psychiatry* 2003;160:883–889
 29. Mitchell JD, Brown ES, Rush AJ. Comorbid disorders in patients with bipolar disorder and concomitant substance dependence. *J Affect Disord* 2007;102:281–287
 30. Back SE, Sonne SC, Killeen T, et al. Comparative profiles of women with PTSD and comorbid cocaine or alcohol dependence. *Am J Drug Alcohol Abuse* 2003;29:169–189
 31. Parrott DJ, Drobes DJ, Saladin ME, et al. Perpetration of partner violence: effects of cocaine and alcohol dependence and posttraumatic stress disorder. *Addict Behav* 2003;28:1587–1602
 32. Heil SH, Badger GJ, Higgins ST. Alcohol dependence among cocaine-dependent outpatients: demographics, drug use, treatment outcome and other characteristics. *J Stud Alcohol* 2001;62:14–22
 33. Salloum IM, Douaihy A, Ndimbie OK, et al. Concurrent alcohol and cocaine dependence impact on physical health among psychiatric patients. *J Addict Dis* 2004;23:71–81
 34. Bray JW, Zarkin GA, Dennis ML, et al. Symptoms of dependence, multiple substance use, and labor market outcomes. *Am J Drug Alcohol Abuse* 2000;26:77–95
 35. MacKinnon DF, Zandi PP, Gershon ES, et al. Association of rapid mood switching with panic disorder and familial panic risk in familial bipolar disorder. *Am J Psychiatry* 2003;160:1696–1698
 36. MacKinnon DF, Zandi PP, Cooper J, et al. Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. *Am J Psychiatry* 2002;159:30–35
 37. Saunders EH, Scott LJ, McInnis MG, et al. Familiality and diagnostic patterns of subphenotypes in the National Institutes of Mental Health Bipolar sample. *Am J Med Genet B Neuropsychiatr Genet* 2007;147B:18–26
 38. Rotondo A, Mazzanti C, Dell'Osso L, et al. Catechol O-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder with and without comorbid panic disorder. *Am J Psychiatry* 2002;159:23–29
 39. Simon NM, Otto MW, Fischmann D, et al. Panic disorder and bipolar disorder: anxiety sensitivity as a potential mediator of panic during manic states. *J Affect Disord* 2005;87:101–105
 40. Goodwin RD, Hoven CW. Bipolar-panic comorbidity in the general population: prevalence and associated morbidity. *J Affect Disord* 2002;70:27–33
 41. Birmaher B, Kennah A, Brent D, et al. Is bipolar disorder specifically associated with panic disorder in youths? *J Clin Psychiatry* 2002;63:414–419
 42. Masi G, Perugi G, Millepiedi S, et al. Clinical and research implications of panic-bipolar comorbidity in children and adolescents. *Psychiatry Res* 2007;153:47–54
 43. Frank E, Cyranowski JM, Rucci P, et al. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar disorder. *Arch Gen Psychiatry* 2002;59:905–911
 44. Feske U, Frank E, Mallinger A, et al. Anxiety as a correlate of response to the acute treatment of bipolar disorder. *Am J Psychiatry* 2000;157:956–962